Responding to growing pressure, ViiV Healthcare announced steps to widen access to its HIV prevention medicine in low- and ...

The announcement marks another important milestone in our efforts to accelerate access to the only long-acting PrEP available ...

ViiV Healthcare, the specialist HIV company majority owned by GSK (LSE: GSK), today announced the presentation of new ...

ViiV Healthcare sponsored events to address the climbing rates of HIV infections on HBCU campuses and the surrounding Black ...

Harmony Garges, M.D, senior vice president, chief medical officer and head of global medical at ViiV Healthcare, highlighted ...

With Gilead sprinting to a likely approval next year for its long-acting pre-exposure | With GSK girding for competition from ...

The survey also found that flexible and virtual appointments, as well as transportation support, were helpful while on ...

At Alabama State University's homecoming, ViiV Healthcare partnered with the campus to raise awareness about HIV prevention, ...

The Indian Patent Office has rejected Viiv Healthcare's patent application for the HIV drug, dolutegravir, after nearly a ...

Studies from OPERA and Trio cohorts provide further real-world evidence supporting CAB LA for PrEP’s high effectiveness and adherence in preventing HIV acquisition Patient-reported results for CAB LA ...

ViiV Healthcare’s latest HIV prevention campaign coincided with one of the biggest weekends of the year at Alabama State ...

ViiV’s strategy for CAB LA for PrEP in L&MICs is to maximise rapid access and uptake for populations with highest unmet needs ...